ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 443

Secreted Frizzled-Related Protein 5 Exerts the Anti-Inflammatory Role in Rheumatoid Arthritis Via Down-Regulation of c-Jun N-Terminal Kinase

Yong-Jin Kwon1, Tae-Yeon Kim2, Sang-Won Lee3, Yong-Beom Park3, Soo Kon Lee4 and Min-Chan Park1, 1Department of Internal Medicine, Yonse University College of Medicine, Seoul, South Korea, 2Dept. of Internal Medicine, Yonse University College of Medicine, Seoul, South Korea, 3Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, 4Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Adipocytokines and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Human Etiology and Pathogenisis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Secreted frizzled-related protein 5 (Sfrp5) is a novel adipokine that has beneficial effects on metabolic dysfunction by controlling inflammatory cells within adipose tissue. Sfrp5 acts as a soluble modulator that binds and sequesters Wnt proteins in the extracellular space and that prevents the activation of frizzled and attenuating non-canonical Wnt signaling. Consequentially, c-Jun N-terminal kinase (JNK), a downstream target of non-canonical Wnt signaling, is inhibited. The purposes of this study are to determine the expression of Sfrp5 in fibroblast-like synoviocyte (FLS) from rheumatoid arthritis (RA) patients and to investigate the correlation between the expression levels of Sfrp5 and that of pro-inflammatory genes in RA FLS.  

Methods:

FLS were isolated and cultured from synovial tissues obtained from patients with RA or osteoarthritis (OA) during total knee replacement surgery. The mRNA expressions of Sfrp5 in peripheral blood mononuclear cells (PBMCs) and FLS from patients with RA or OA were determined using real-time quantitative RT-PCR. Adenovirus containing Sfrp5 transcript was constructed and delivered into RA FLS to strengthen Sfrp5 expression, then, Sfrp5 RNAi plasmid was transfected to abrogate Sfrp5 expression in RA FLS. The mRNA expressions of TNF-α, IL-1β, IL-6, CCL-2, CCL-7, COX-2 and MMP-9 were also determined using quantitative real-time PCR and western blot analysis was performed to assess MKK4, MKK-7, ATF-2, c-Jun and JNK activity in RA FLS.

Results:

Expression of Sfrp5 mRNA in PMBCs from RA patients was significantly decreased compared to those from OA patients, and this decrease was more accentuated in RA FLS compared to OA FLS (more than 10-fold in OA FLS). The mRNA expressions of TNF-α, IL-1β, IL-6, CCL-2, CCL-7, COX-2 and MMP-9 were remarkably increased in Sfrp5 RNAi plasmid-transfected RA FLS, compared to non-silencing RNAi plasmid-transfected RA FLS. However, adenoviral vectors encoding Sfrp5 significantly reduced the mRNA levels of TNF-α, IL-1β, IL-6, CCL-2, CCL-7, COX-2 and MMP-9 as compared with control vector. The activity of MKK4, MKK-7, ATF-2, c-Jun and JNK were up-regulated in RA FLS with no Sfrp5 expression by Sfrp5 RNAi plasmid; and were down-regulated with strong Sfrp5 expression by adenoviral vectors encoding Sfrp5.

Conclusion:

Sfrp5 suppressed various pro-inflammatory gene expressions via modulation of JNK. These findings suggest that Sfrp5 may have a certain role in RA pathogenesis and have an anti-inflammatory effect.


Disclosure:

Y. J. Kwon,
None;

T. Y. Kim,
None;

S. W. Lee,
None;

Y. B. Park,
None;

S. K. Lee,
None;

M. C. Park,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/secreted-frizzled-related-protein-5-exerts-the-anti-inflammatory-role-in-rheumatoid-arthritis-via-down-regulation-of-c-jun-n-terminal-kinase/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology